Pyxis Oncology, Inc. (PYXS) Wednesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PYX-201, the company's drug candidate for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.